Table 1.
Patients' characteristics.
| Characteristics | FLOX arm | 3-week arm | P value |
|---|---|---|---|
| Age | |||
| Median | 56 | 54 | .45 |
| Range | 44–69 | 41–68 | |
| Gender | |||
| Male | 16 (67%) | 17 (71%) | .49 |
| Female | 8 (33%) | 7 (29%) | .35 |
| Disease at presentation | |||
| Locally advanced | 15 (63%) | 14 (58%) | .44 |
| Metastatic | 9 (37%) | 10 (42%) | .23 |
| Site of metastases | |||
| Liver | 5 (21%) | 6 (25%) | .48 |
| Lung | 1 (4%) | 1 (4%) | — |
| LN | 2 (8%) | 2 (8%) | — |
| Peritoneal | 1 (4%) | 1 (4%) | — |
| others | — | ||
| Previous surgery | |||
| Palliative | 5 (21%) | 4 (17%) | .3 |
| Radical | 1 (4%) | 1 (4%) | — |
| None | |||
| Prior chemotherapy | |||
| Gemcitabine single agent | 14 (58%) | 16 (67%) | .23 |
| Gem + 5FU | 8 (34%) | 6 (25%) | .17 |
| Gem + Platinol | 2 (8%) | 2 (8%) | — |
| Response to prior therapy | |||
| Partial response | — | — | |
| Stable disease | 2 (8%) | 3 (12.5%) | .12 |
| Progression | 22 (92%) | 21 (87.5%) | .27 |
| Presented symptoms | |||
| Pain | 8 (34%) | 8 (34%) | — |
| Weight loss | 20 (84%) | 20 (84%) | — |